MicroPort Scientific Corporation (MCRPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MicroPort Scientific Corporation (MCRPF) trades at $0.85 with AI Score 59/100 (Grade B). MicroPort Scientific Corporation manufactures and distributes medical devices globally. Market cap: $1.63B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for MCRPF: MCRPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCRPF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MCRPF: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →MicroPort Scientific Corporation (MCRPF) Healthcare & Pipeline Overview
MicroPort Scientific Corporation is a global medical device company specializing in cardiovascular, orthopedic, and surgical robotic solutions. With a focus on innovation and international expansion, MicroPort serves diverse markets, including China, North America, and Europe, positioning itself as a key player in the medical device industry.
What Is the Investment Thesis for MCRPF?
MicroPort Scientific Corporation presents a mixed investment thesis. The company's diverse product portfolio across multiple high-growth medical device segments, including surgical robotics and cardiovascular devices, offers significant growth potential. Expansion into international markets, particularly in emerging economies, could drive revenue growth. However, the company's negative profit margin of -16.1% and negative P/E ratio of -12.91 raise concerns about profitability. Successful commercialization of its surgical robot technologies and continued innovation in its core cardiovascular and orthopedic segments are key to future success. Investors should closely monitor the company's ability to improve profitability and manage its operating expenses.
Based on FMP financials and quantitative analysis
MCRPF Key Highlights
- Market Cap of $1.63B reflects its position as a significant player in the medical device market.
- Gross Margin of 54.1% indicates strong pricing power and efficient manufacturing processes.
- Operating in multiple segments including Cardiovascular Devices, Orthopedics Devices, and Surgical Robot Business, diversifying its revenue streams.
- Global presence in the People's Republic of China, North America, Europe, other Asian countries, and South America.
- Beta of 0.39 suggests lower volatility compared to the overall market.
Who Are MCRPF's Competitors?
MCRPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APNHF Aspen Pharmacare Holdings Limited | $8.20 | -5.75% | $3.64B | 50 |
| GGNDF GN Store Nord A/S | $14.35 | +7.17% | $2.09B | 41 |
| GNNDY GN Store Nord A/S | $41.25 | -0.10% | $2.00B | 44 |
| HAWPY Haw Par Corporation Limited | $54.44 | +1.76% | $3.01B | 50 |
| JXFGF Jinxin Fertility Group Limited | $1.00 | +244.83% | $2.56B | 49 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCRPF's Key Strengths?
- Diverse product portfolio across multiple medical device segments.
- Strong presence in China and other emerging markets.
- Innovative surgical robotics platform.
- Established brand reputation and relationships with healthcare providers.
What Are MCRPF's Weaknesses?
- Negative profit margin and P/E ratio.
- High operating expenses.
- Dependence on regulatory approvals for new products.
- Exposure to currency fluctuations.
What Could Drive MCRPF Stock Higher?
- Regulatory approvals for new medical devices in key markets.
- Commercialization of surgical robots in China and other emerging markets.
- Expansion of distribution network and partnerships with healthcare providers.
- Continued innovation in cardiovascular and orthopedic devices.
- Strategic acquisitions to expand product portfolio and geographic reach.
What Are the Key Risks for MCRPF?
- Financial-distress signal — its Altman Z-Score of 0.46 sits in the distress zone (elevated bankruptcy risk).
- Intense competition from established medical device companies.
- Stringent regulatory requirements and product recalls.
- Pricing pressures from healthcare providers and payers.
- Negative profit margin and high operating expenses.
- Dependence on regulatory approvals for new products.
What Are the Growth Opportunities for MCRPF?
- Expansion of Surgical Robotics Business: MicroPort's Surgical Robot Business segment represents a significant growth opportunity. The global surgical robotics market is projected to reach $14.4 billion by 2026, growing at a CAGR of 12.7%. Successful commercialization of its surgical robots, particularly in China and other emerging markets, could drive substantial revenue growth. The company's focus on developing cost-effective and versatile robotic platforms could provide a competitive advantage.
- Penetration of Emerging Markets: Expanding its presence in emerging markets, particularly in Asia and South America, offers significant growth potential. These markets are experiencing rapid growth in healthcare expenditure and increasing demand for advanced medical devices. MicroPort's established presence in China provides a strong foundation for expanding into other Asian markets. Tailoring its products and services to meet the specific needs of these markets could drive revenue growth.
- Innovation in Cardiovascular Devices: Continued innovation in its Cardiovascular Devices segment, including the development of next-generation stents and delivery systems, is crucial for maintaining its competitive position. The global cardiovascular devices market is projected to reach $60 billion by 2026. Focusing on developing innovative solutions for complex coronary artery diseases and expanding its product portfolio to include new therapeutic areas could drive growth.
- Growth in Orthopedic Devices: The Orthopedics Devices segment offers growth opportunities through the development of advanced implants and surgical techniques. The global orthopedic devices market is projected to reach $55 billion by 2026. Focusing on developing personalized implants and minimally invasive surgical solutions could drive growth in this segment. Expanding its distribution network and strengthening its relationships with orthopedic surgeons are also important for success.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships to expand its product portfolio and geographic reach represents another growth opportunity. Acquiring companies with complementary technologies or established market positions could accelerate its growth and enhance its competitive advantage. Partnering with leading research institutions and healthcare providers could also drive innovation and improve its market access.
What Opportunities Does MCRPF Have?
- Expansion of surgical robotics business.
- Penetration of emerging markets.
- Innovation in cardiovascular and orthopedic devices.
- Strategic acquisitions and partnerships.
What Threats Does MCRPF Face?
- Intense competition from established medical device companies.
- Stringent regulatory requirements and product recalls.
- Pricing pressures from healthcare providers and payers.
- Economic slowdown in key markets.
What Are MCRPF's Competitive Advantages?
- Strong brand reputation in the medical device industry.
- Extensive product portfolio across multiple therapeutic areas.
- Established presence in China and other emerging markets.
- Proprietary technologies and intellectual property.
- Strong relationships with key opinion leaders and healthcare providers.
What Does MCRPF Do?
Founded in 1998 and headquartered in Shanghai, China, MicroPort Scientific Corporation has evolved into a prominent global medical device company. The company's initial focus was on developing and manufacturing cardiovascular devices, specifically coronary stents, to address the growing need for advanced cardiac care in China. Over the years, MicroPort expanded its product portfolio through strategic acquisitions and internal research and development, venturing into orthopedics, cardiac rhythm management, endovascular solutions, neurovascular devices, heart valve technologies, surgical robots, and surgical devices. Today, MicroPort operates through several key segments. The Cardiovascular Devices segment offers coronary stents and related delivery systems. The Orthopedics Devices segment provides reconstructive joints and spine implants. The Cardiac Rhythm Management Business segment offers defibrillators and pacemakers. The Endovascular and Peripheral Vascular Devices segment provides products for aortic and peripheral vascular diseases. The Neurovascular Devices segment offers neurovascular therapeutic devices. The Heart Valve Business segment provides transcatheter aortic valves. The Surgical Robot Business segment designs surgical robots. The Surgical Devices segment researches and sells surgical devices. MicroPort distributes its products across China, North America, Europe, and other international markets.
What Products and Services Does MCRPF Offer?
- Manufactures and distributes medical devices globally.
- Offers products for cardiovascular diseases, including coronary stents and delivery systems.
- Provides orthopedic implants for reconstructive joint surgery and spine procedures.
- Develops and markets cardiac rhythm management devices, such as defibrillators and pacemakers.
- Offers endovascular and peripheral vascular devices for treating aortic and vascular diseases.
- Provides neurovascular devices for treating neurovascular diseases.
- Develops and commercializes surgical robots for various surgical procedures.
- Manufactures and sells surgical devices.
How Does MCRPF Make Money?
- Develops, manufactures, and markets a broad range of medical devices.
- Generates revenue through the sale of its products to hospitals, clinics, and healthcare providers.
- Invests in research and development to innovate and expand its product portfolio.
- Distributes its products through a network of sales representatives and distributors.
- Focuses on international expansion to drive revenue growth.
What Industry Does MCRPF Operate In?
The medical device industry is characterized by continuous innovation, stringent regulatory requirements, and increasing demand driven by an aging global population and rising healthcare expenditure. MicroPort Scientific Corporation operates in a competitive landscape that includes major players like Medtronic, Johnson & Johnson, and Stryker, as well as specialized competitors in each of its segments. The industry is experiencing growth in minimally invasive surgery, robotic surgery, and personalized medicine, creating opportunities for MicroPort to leverage its R&D capabilities and expand its market share. The global medical devices market is projected to reach $600 billion by 2026, with a CAGR of 5.4%.
Who Are MCRPF's Key Customers?
- Hospitals and clinics
- Healthcare providers
- Surgeons and interventional cardiologists
- Patients requiring medical device implants and therapies
- Distributors and sales representatives
FY2026 estForward Outlook
Wall Street analysts project MicroPort Scientific Corporation revenue of about $1.18B for fiscal 2026, with EPS near $0.05. The estimate reflects 7 contributing analysts.
F-Score 4/9Financial Health
MicroPort Scientific Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.46 places it in the distress zone, a signal of elevated financial risk.
ROE 6%Key Financial Metrics
Return on equity for MicroPort Scientific Corporation stands at 6.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.3%, showing how much profit it generates from its asset base. MCRPF trades at a trailing price-to-earnings ratio of 27.12, above the Healthcare sector average of ~23x. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.7%, the inverse of the P/E and a quick read on earnings relative to price.
MicroPort Scientific Corporation (MCRPF) Valuation Context
Valued at $1.63B, MCRPF is classified as a small-cap stock. Relative to its peer group, MCRPF's quantitative score of 59/100 is above the peer average of 47/100.
Company Profile
MicroPort Scientific Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Jonathon W. Chen. MCRPF has traded publicly since 2012.
MCRPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio across multiple medical device segments.
- Strong presence in China and other emerging markets.
- Innovative surgical robotics platform.
- Established brand reputation and relationships with healthcare providers.
Bear Case
- Negative profit margin and P/E ratio.
- High operating expenses.
- Dependence on regulatory approvals for new products.
- Exposure to currency fluctuations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MCRPF Latest News
No recent news available for MCRPF.
MCRPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCRPF.
Price Targets
Wall Street price target analysis for MCRPF.
MCRPF MoonshotScore
What does this score mean?
The MoonshotScore rates MCRPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zhaohua Chang
CEO
Zhaohua Chang is the Chief Executive Officer of MicroPort Scientific Corporation. His background includes extensive experience in the medical device industry, with a focus on strategic planning, business development, and operational management. He has been instrumental in driving the company's growth and expansion into new markets. His leadership is focused on innovation and globalization.
Track Record: Under Zhaohua Chang's leadership, MicroPort Scientific Corporation has expanded its product portfolio and strengthened its presence in key markets. He has overseen the development and commercialization of innovative medical devices, including surgical robots and advanced cardiovascular solutions. He is managing 6347 employees.
MCRPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MicroPort Scientific Corporation may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Lower liquidity can lead to difficulty in buying or selling shares.
- Wider bid-ask spreads can result in higher transaction costs.
- Less regulatory oversight increases the risk of mismanagement and corporate governance issues.
- Higher price volatility can lead to significant losses.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and bid-ask spreads.
- Consult with a financial advisor.
- Established presence in the medical device industry.
- Global operations and distribution network.
- Diverse product portfolio across multiple therapeutic areas.
- Focus on innovation and research and development.
- Experienced management team.
Common Questions About MCRPF (Healthcare)
What does MicroPort Scientific Corporation do?
MicroPort Scientific Corporation is a global medical device company that develops, manufactures, and markets a wide range of medical devices. The company's product portfolio includes cardiovascular devices, orthopedic implants, cardiac rhythm management devices, endovascular solutions, neurovascular devices, heart valve technologies, surgical robots, and surgical devices. MicroPort serves hospitals, clinics, and healthcare providers in China, North America, Europe, and other international markets.
What do analysts say about MCRPF stock?
Analyst coverage of MCRPF is limited due to its OTC listing. However, the company's growth potential in the medical device industry, particularly in surgical robotics and emerging markets, is generally viewed positively. Key valuation metrics, such as its negative P/E ratio, reflect its current lack of profitability. Investors may want to evaluate the company's growth prospects, competitive landscape, and financial performance when evaluating MCRPF stock.
What are the main risks for MCRPF?
The main risks for MicroPort Scientific Corporation include intense competition from established medical device companies, stringent regulatory requirements and product recalls, pricing pressures from healthcare providers and payers, its negative profit margin and high operating expenses, and its dependence on regulatory approvals for new products. Additionally, its OTC listing exposes investors to risks associated with limited financial disclosure and liquidity.
What are the key factors to evaluate for MCRPF?
MicroPort Scientific Corporation (MCRPF) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does MCRPF data refresh on this page?
MCRPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MCRPF's recent stock price performance?
MicroPort Scientific Corporation (MCRPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple medical device segments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCRPF overvalued or undervalued right now?
Valuing MicroPort Scientific Corporation (MCRPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MCRPF?
Before investing in MicroPort Scientific Corporation (MCRPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available public information.